• Home
  • About
    • Group CEO
    • Management Team
    • Supervisory Board
    • Scientific Advisory Board
    • Affiliates
    • R&D Partnerships
    • Distributors
    • Quality Standards
    • Location
  • Services
    • Proteomics
    • Genomics Transcriptomics
    • Flow Cytometry
    • Assay Development
    • Monoclonal Antibodies
    • Biobanking
    • OLINK Services
    • Biomarker Data Analyses
  • R&D
  • Products
    • MEMORYLINC
    • NEUROLINCS
    • FIMICS
    • BIOPRED
    • IVD Products
    • ELISA Kits
    • Recombinant Proteins
    • Monoclonal Abodies
    • Clinical Samples
    • Your Customized Kit
  • Quality
  • Investors
    • Financial Management
    • Financial Data
    • Shareholders
  • Media
    • Press Releases
    • Media News
    • Newsletters
    • Posts
    • All Media
  • Careers
  • IFU APO-Easy
Contact
Firalis
  • Home
  • About
  • Services
  • Products
  • R&D
  • Quality
  • Investors
  • Media
  • 776-npcibak8wpk.jpg

    OLINK Services (Explore & Target)

    cutting-edge services on Olink's high-multiplex, high-throughput protein biomarker platform

  • 776-dfqfzgxvsc.jpg

    PROTEOMICS Services

    Immunoassays to measure circulating and soluble markers

  • 776-frwocvisp8u.jpg

    GENOMICS Services

    From Next-Generation Sequencing to qRT-PCR, complete solutions for genomic and transcriptomic discovery & profiling

  • 776-arqiv4kqnra.jpg

    ASSAY DEVELOPMENT Services

    Development of custom assays meeting your specific requirements

  • 123-brkikonp0kq.jpg

    NEUROLINCS

    targeted sequencing panel that quantifies ~7500 brain enriched lncRNAs associated with cognitive impairment, Alzheimer's, and other neurodegenerative diseases

  • 776-hybxy5phqr8.jpg

    BIOPRED

    an mRNA based targeted gene sequencing panel to better understand inflammatory-autoimmune disorders

  • 776-rg1lnufgjhi.jpg

    FIMICS

    a long non-coding RNA panel to better characterize patients with cardiac disorders and toxicities

  • 776-rkjyubm92mm.jpg

    ELISA KITS

    Colorimetric sandwich ELISA kits developed and validated for biomarker measurement in blood-derived matrices samples

the reliable partner

since its creation, Firalis Group has been awarded for and contributed in

more than a hundred high-ranked clinical and pre-clinical research projects in biomarkers,

playing a leading role towards the setting of industry gold standards

for the discovery, development and qualification of

novel biomarkers for clinical and pre-clinical applications!

126-whyfiralis.png

Why Firalis

Firalis provides a comprehensive range of biomarker services from research to clinical qualification. Stratification at scientific and technical levels support biomarker discovery, validation, evaluation and qualification. Using our strong expertise and cutting-edge laboratory equipment, we develop and deliver customized solutions for biomarker assays according to your project needs.

129-whoweare.png
Who we are

Firalis is involved in several large scale projects for qualification of biomarkers in various clinical applications and led the efforts to improve industry standards, as the initiator of the SAFE-T consortium, largest ever biomarker research project co-funded by EU-IMI and Pharma.Today, Firalis validates and develops biomarker panels, following strictly
the EMA and FDA directions.

030548264132-whatwedo.png

What we do

Firalis' bioanalytical tools are developed

in a GMP compliant production facility certified with "ISO 13485", the international norm for medical device manufacture

and biomarker services are performed in laboratories certified with "ISO 17025",

the most important quality standard

for calibration and testing.

Recent news at Firalis

COVIRNA Project Final Conference takes place on 19-April-23

COVIRNA Project end date is approaching, with the final conference that will take place in Brussels on the 19th of April, 2023.

07.04.2023

Read More

PARADISE Project launches with a kick-off held in Dublin (3-4 April 2023)

To develop a personalised prediction tool for better management of autoimmune diseases recurrence, PARADISE Project kicked off on 3 -4 April 2023 in Dublin, coordinated by ADAPT at Trinity College of Dublin, with partners across several European institutions, including FIRALIS.

05.04.2023

Read More

Bpifrance funds Firalis’ Alzheimer Project!

FIRALIS’ Research on Neurodegenerative Diseases obtains Bpifrance Funding!

09.08.2022

Read More

FIRALIS obtains ISO 14001 International Quality Standard !

FIRALIS obtained the AFNOR certification “ISO 14001”, a gold standard in improving the environmental performance!

11.07.2022

Read More

Load More

Contact Firalis

Firalis Group

© Copyright 2020 all rights reserved. 

The company logos, products and service marks are trademarks or registered trademarks of Firalis.

-----------------------------------------------------------------------------------------------------------------------

Information addressed to health professionals. The products presented on this site are for professional use only and, where applicable, comply with the requirements of the IVD Directive 98/79 / EC. Instructions for use must be consulted before using these products.

-----------------------------------------------------------------------------------------------------------------------

Headquarter : 17 Rue du Fort 68330 Huningue FRANCE